Synlogic Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
Synlogic is a clinical-stage biotechnology company based in Cambridge, Massachusetts. It focuses on developing oral, non-systemically absorbed biotherapeutics for serious diseases, using its Synthetic Biotic platform to engineer probiotics into GI-restricted medicines that modulate disease-related metabolites. Its late-stage pipeline is led by SYNB1934 (labafenogene marselecobac) for phenylketonuria (PKU), currently studied in the global pivotal Phase 3 trial Synpheny-3, with additional candidates targeting homocystinuria, enteric hyperoxaluria, gout, and cystinuria. The company maintains research collaborations, including a Roche partnership focused on inflammatory bowel disease and a collaboration with Ginkgo Bioworks that has contributed to two pipeline programs. Synlogic employs between 11 and 50 people and maintains more information at https://synlogictx.com.